Longevity Health extends cash runway into 1Q26
Longevity Health (XAGE) Holdings announced the sale of 479,621 shares of its common stock at an average price of $4.08 per share through its at-the-market equity offering facility. Gross proceeds from the ATM sales totaled approximately $1.96M, prior to deducting fees and expenses. Assuming no growth beyond the Company's pro forma consolidated FY24 sales and not factoring in the planned 20/20 merger, this financing extends XAGE's cash runway into Q1 FY26.
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders' Hot Stocks on TipRanks >>
Read More on XAGE:
Disclaimer & DisclosureReport an Issue
Longevity Health Gains Nasdaq Approval for Listing
Longevity announces continued Nasdaq listing to complete 20/20 BioLabs deal
Longevity Health reports unaudited Q1 revenue $663,000, up 8% year-over-year
Longevity Health Holdings Inc trading halted, news pending
Longevity Health Implements Reverse Stock Split
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Why Intel's (INTC) Comeback Might Happen Sooner Than Expected
As an investor who's watched Intel's (INTC) challenges unfold over the past few years, I'm genuinely excited about Lip-Bu Tan stepping in as CEO. Tan's approach is both bold and strategic—the exact combination Intel desperately needs. He's already making aggressive moves to restructure the company, ramp up investments in manufacturing and AI, and put the foundry business at the forefront. Despite the plethora of both internal and external turmoil, INTC stock has managed to post a flat first six months of 2025. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Tan is steering Intel not only to reclaim its former dominance but potentially to exceed it. I'm bullish on the outlook—but realistic, too—knowing it will take time for Intel to solidify its AI foothold and deliver meaningful returns in the years ahead. Since taking the helm as CEO in March 2025, Tan has wasted no time launching a significant restructuring to slash layers of middle management that have long bogged down Intel's innovation and decision-making. The plan calls for reducing the workforce by about 20%—a tough but necessary move to streamline the organization and accelerate its agility. This isn't just about trimming costs; it's about making Intel leaner and faster. The company aims to reduce operating expenses to around $17 billion by FY 2025. While layoffs are never easy, Intel has grown bloated compared to rivals and now faces an intensely competitive market where survival—and success—demand swift action. As things stand, Intel lags behind its sector peers on several key metrics. I'm confident that a leaner Intel will be sharper, faster, and better positioned to innovate boldly and prove its strength to the competition. However, Tan must handle the workforce cuts with care, focusing on retaining key talent and maintaining morale through a strong, principled leadership approach. Arguably, Tan's boldest move is his unwavering commitment to Intel's advanced manufacturing, especially the cutting-edge 18A node (1.8nm) technology. Set to power Intel's Panther Lake CPUs by late 2025, this breakthrough could dramatically boost energy efficiency and performance, potentially allowing Intel to finally compete toe-to-toe with giants like TSMC (TSM) and Samsung (SSNLF). On the foundry front, Intel Foundry Services (IFS) is gaining serious momentum. High-profile deals—most notably with Microsoft (MSFT)—to utilize Intel's 18A process could transform Intel into a fierce contender in the foundry market. Securing a few more marquee contracts from the likes of Nvidia (NVDA) or Apple (AAPL) would be a game-changer, sparking a significant surge in investor confidence and substantially lifting Intel's valuation. That said, delays in the massive Ohio manufacturing facility, now pushed back to around 2030, raise concerns about capacity constraints and potential missed opportunities if chip demand suddenly spikes. Intel's challenge going forward will be striking the right balance in capital allocation and maintaining a nimble leadership team ready to seize emerging market opportunities quickly. Looking ahead to 2028, Intel's financial health will largely depend on how well it executes its strategy. Analysts project relatively flat to slightly declining revenue in FY 2025, hovering between $50 billion and $53 billion, with a modest recovery expected afterward. Earnings per share of around $0.30 for 2025 seem reasonable, given the current margin pressures. In my base-case outlook, Intel modestly rebounds to about $60 billion in revenue by 2028, with earnings per share approaching $3.00. This scenario would support a share price rising to around $40 from today's $20—a steady but unspectacular return over three years, especially with the dividend still cut during the turnaround. However, in a bull-case scenario, if Intel secures major foundry contracts and capitalizes on strong AI-driven demand, earnings per share could reach $5.00 by 2028, pushing shares into the $70 to $90 range. Conversely, if Intel falters in execution, revenue stagnates, and growth stalls, the stock could remain stuck in the $20s with limited upside potential. Intel is facing significant challenges, and execution, especially talent retention and deployment, will be critical. Any delays or yield issues with the 18A node could undermine confidence and push foundry customers toward competitors like TSMC. Additionally, Intel faces intense competition in chip design from Nvidia (NVDA) and AMD (AMD). Still, I believe the opportunities outweigh the risks. Despite dominant rivals, Intel's valuation remains attractively low, with a price-to-sales ratio under 2, compared to TSMC's 8.5, leaving plenty of room for multiple expansion as earnings momentum improves and investor sentiment turns positive. History shows that undervalued companies staging a comeback can deliver compelling investment stories. When it comes to INTC, most of Wall Street is sitting on the fence. Intel carries a consensus Hold rating, backed by two Buys, 25 Holds, and four Sells. INTC's average stock price target is $21.29, suggesting roughly 6.5% upside over the next year. Although this suggests it may be premature to expect significant gains, investors who buy now and hold through the stagnation phase could reap rewards if sentiment improves—truly a case of being better off being early than too late. There's no guarantee Intel will pull off a complete turnaround, but the company is clearly taking bold steps to tackle years of bloat, strategic drift, and technological lag. Still, winning over a competitive market dominated by entrenched giants won't be easy—it will require grit from management, sharp strategic vision, and a bit of luck. That said, for portfolios seeking value-driven upside, a modest stake in Intel could be a worthwhile investment. I'm cautiously optimistic. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
37 minutes ago
- Yahoo
Sharps Technology CEO, Robert Hayes, to Present at the Virtual Investor Summit on June 10, 2025
Presentation to be webcast live at 10:00 AM ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (Nasdaq: 'STSS' and 'STSSW') ('Sharps'), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart safety syringe products to the healthcare industry, today announced that Robert Hayes, CEO, will present at the Virtual Investor Summit on June 10, 2025, at 10:00 AM ET. Investors are invited to listen to the presentation and can register here. Sharps recently announced that the Company has commenced shipments under three customer orders tied to previously announced purchase agreements. These shipments represent the Company's first commercial deliveries and its transition to revenue-generating operations. All products are being manufactured and shipped from Sharps' facility in Hungary, which has undergone significant upgrades to support high-volume production. Read the update release HERE. Presentation Details: Event: Q2 Investor Summit Date & Time: 10:00 AM ET on June 10, 2025 Presenter: Robert Hayes, CEO Webcast: LINK HERE Conference Overview and Structure:The Investor Summit is an exclusive event tailored for investors focused on small- and micro-cap stocks. It offers a unique opportunity to meet with management teams from high-potential emerging companies, gain insights from industry experts, and understand how peers are navigating the current market environment. This quarter's event centers on micro-cap companies that are currently undervalued and positioned near catalyst events that could significantly accelerate their growth trajectory. Registration for Investors:To request free registration, please go to the Investor Summit website, ( and click the "Registration" button. For More Information, please visit: or, contact johnna-mae@ About Sharps Technology:Sharps Technology is an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry. The Company's product lines focus on providing ultra-low waste capabilities, that incorporate syringe technologies that use both passive and active safety features. Sharps also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. The Company has a manufacturing facility in Hungary. For additional information, please visit FORWARD-LOOKING STATEMENTS:This press release contains 'forward-looking statements'. Forward-looking statements reflect our current view about future events. When used in this press release, the words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'future,' 'intend,' 'plan,' 'poised' or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity, and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance, or achievements. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Investor Contact:Holdsworth PartnersAdam HoldsworthPhone: 917-497-9287Email: IR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Top Stock Movers Now: Warner Bros. Discovery, Boeing, Sunnova, and more
U.S. equities were mixed and little changed at midday as the market focused on new trade talks between the U.S. and China. Warner Bros. Discovery will split its TV properties from its streaming and movie studio businesses. Rooftop solar power provider Sunnova Energy International filed for bankruptcy as demand for solar panels in homes tumbles.U.S. equities were mixed and little changed at midday as the markets awaited any news from the trade talks between the U.S. and China that began today. The S&P 500 and Nasdaq rose, but the Dow Jones Industrial Average fell. Warner Bros. Discovery (WBD) was the best-performing stock in the S&P 500 after the media giant announced it was splitting itself into two publicly traded companies, dividing its television properties from its streaming and studio businesses. Shares of Boeing (BA) gained when the aircraft maker landed its first plane in China after the easing of trade tensions with the U.S. led Beijing to allow deliveries of its jets again. Qualcomm (QCOM) shares rose when the chipmaker purchased British-based wired connectivity firm Alphawave for $2.4 billion, boosting its expansion into artificial intelligence (AI) data centers. Intuitive Surgical (ISRG) shares slumped as Deutsche Bank downgraded the stock and lowered the price target, pointing to increased competition for the maker of the da Vinci surgical robot. Shares of The Children's Place (PLCE) sank when the children's products retailer's loss soared and sales fell short of estimates, which it blamed on consumer concerns about the economy and tariffs. Trading in Sunnova Energy International (NOVA) was halted after shares plunged 30% in the premarket when the rooftop solar provider filed for bankruptcy as demand for residential solar panels sinks. Oil and gold futures advanced. The yield on the 10-year Treasury note declined. The U.S. dollar lost ground to the euro, pound, and yen. Prices for most major cryptocurrencies were higher. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
